AIM： To investigate the expression of midkine in eso- phageal squamous cell carcinoma （ESCC） and analyze its relationship with clinicopathological features. METHODS： RT-PCR and immunocytochemical staining were use...AIM： To investigate the expression of midkine in eso- phageal squamous cell carcinoma （ESCC） and analyze its relationship with clinicopathological features. METHODS： RT-PCR and immunocytochemical staining were used to detect the expression of midkine mRNA and protein in EC109 cells, respectively. Then the expression of midkine in 66 cases of ESCC samples were detected by immunohistochemistry using monoclonal antibodies against human midkine. RESULTS： Midkine was expressed in EC109 cell by RT- PCR and imrnunocytochemistry. The immunoreactivity was detected in 56.1% （37/66） of the ESCC samples. The expression of midkine was found in cytoplasm of tumor cells. Notably, the intensity of midkine was stronger at the area abundant in vessels and the invading border of the tumors. Midkine was more intensely expressed in well differentiated tumors （76.9 %） than in moderately and poorly differentiated tumors （43.1% and 41.2%, respectively） （P〈0.05）. There was no statistically significant correlation between midkine expression and gender, age, clinical stage, lymph node metastasis or survival in ESCC. CONCLUSION： IVlidkine is overexpressed in ESCC. It may play a role in tumor angiogenesis and invasion. The expression of midkine is correlated with tumor cell differentiation in ESCC. The more poorly tumor cells differentiate, the weaker midkine expresses.展开更多
基金Supported by Beijing Science and Technology Committee Molecular Oncology Laboratory Fund (No. 953850500)National Key Basic Research and Development Project 973 Fund, No. 2004CB518708
文摘AIM： To investigate the expression of midkine in eso- phageal squamous cell carcinoma （ESCC） and analyze its relationship with clinicopathological features. METHODS： RT-PCR and immunocytochemical staining were used to detect the expression of midkine mRNA and protein in EC109 cells, respectively. Then the expression of midkine in 66 cases of ESCC samples were detected by immunohistochemistry using monoclonal antibodies against human midkine. RESULTS： Midkine was expressed in EC109 cell by RT- PCR and imrnunocytochemistry. The immunoreactivity was detected in 56.1% （37/66） of the ESCC samples. The expression of midkine was found in cytoplasm of tumor cells. Notably, the intensity of midkine was stronger at the area abundant in vessels and the invading border of the tumors. Midkine was more intensely expressed in well differentiated tumors （76.9 %） than in moderately and poorly differentiated tumors （43.1% and 41.2%, respectively） （P〈0.05）. There was no statistically significant correlation between midkine expression and gender, age, clinical stage, lymph node metastasis or survival in ESCC. CONCLUSION： IVlidkine is overexpressed in ESCC. It may play a role in tumor angiogenesis and invasion. The expression of midkine is correlated with tumor cell differentiation in ESCC. The more poorly tumor cells differentiate, the weaker midkine expresses.
